Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease

Haematologica

Volumn 99, Issue 2, 2014, Pages 385-391

  Inamoto, Yoshihiro ^a   Martin, Paul J ^a,b   Storer, Barry E ^a,b   Mielcarek, Marco ^a,b   Storb, Rainer F ^a,b   Carpenter, Paul A ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FAILURE FREE SURVIVAL; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PREDICTIVE VALUE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UNRELATED DONORS;

ADOLESCENT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84896723995     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.093062     Document Type: Article

References (17)

1. Bacigalupo A. Management of acute graftversus-host disease. Br J Haematol. 2007; 137(2):87-98.
2. Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009;114(20):4327-36.
3. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115(26):5412-7.
4. Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolanos-Meade J, et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant. 2010;16 (12):1693-9.
5. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 2012;47 (1):125-31.
6. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75(4):1024-30.
7. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versushost disease: initial treatment. Blood. 1990;76(8):1464-72.
8. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8(7): 387-94.
9. Workshop on Clinical Trial Endpoints for Acute Graft-vs-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. 2005 [cited 2012 September 1]; Available from: http://www.cibmtr.org/Meetings/Materials/ GVHDworkshop/pages/index.aspx
10. Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant. 2009;15(7):777-84.
11. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-8.
12. Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, Stern JM, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108(2): 749-55.
13. Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113(13):2888-94.
14. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
15. Inamoto Y, Storer BE, Lee SJ, Carpenter PA, Sandmaier BM, Flowers ME, et al. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 2013;121(12):2340-6.
16. Robin M, Porcher R, de Castro R, Fisher G, de Latour RP, Ribaud P, et al. Initial liver involvement in acute GVHD is predictive for nonrelapse mortality. Transplantation. 2009;88(9): 1131-6.
17. Khera N, Storer B, Flowers ME, Carpenter PA, Inamoto Y, Sandmaier BM, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012; 30(1):71-7.